CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

A bioengineer highlights the potential of low-intensity ultrasound for multiple uses, from enhanced drug delivery to the ...

Rece Hinds can build a nice career in the Cincinnati Reds’ outfield by showing the ability to adjust. Little did he know that ...

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Research shows those who later developed dementia performed significantly worse at the “triangle test” than those who ...

Age-related macular degeneration, or AMD, is a common eye condition and also a leading cause of vision ... The first similar ...

If you’re in your 30s, 40s or 50s, dementia might feel like a distant concern, something you associate with advanced age.

Undergo regular eye examinations (especially in patients with familial amyloidosis) due to amyloid deposition behind the lens. Seek genetic counseling to learn about the risks of passing the ...

A new study reveals that visual sensitivity loss can predict dementia up to 12 years before diagnosis. Researchers found that ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

One of the telltale signs of dementia is forgetfulness, but symptoms can appear more than a decade before an official ...

Investing.com -- Alnylam Pharmaceuticals (NASDAQ: NASDAQ: ALNY) stock climbed 5% as trading resumed on Friday morning, following the company’s announcement that the FDA has approved AMVUTTRA for ...